Immunome (IMNM) Cash & Current Investments (2019 - 2026)

Immunome has reported Cash & Current Investments for 8 years, with the latest figure at $582.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 83.64% year-over-year to $582.7 million; the trailing twelve-month figure through Mar 2026 stood at $582.7 million (up 83.64% YoY), and the FY2025 full-year result was $653.5 million, up 200.72% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $582.7 million, down from $653.5 million in the prior quarter.
• The five-year high for Cash & Current Investments was $653.5 million in Q4 2025, with the low at $20.3 million in Q4 2022.
• Historically, Cash & Current Investments has averaged $210.4 million across 5 years, with a median of $217.3 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Current Investments tumbled 58.72% — and 2024, when it jumped 624.58%.
• Immunome's Cash & Current Investments stood at $20.3 million in 2022, then surged by 579.73% to $138.1 million in 2023, then jumped by 57.3% to $217.3 million in 2024, then surged by 200.72% to $653.5 million in 2025, then slipped by 10.83% to $582.7 million in 2026.
• The last three Cash & Current Investments figures came in at $582.7 million (Q1 2026), $653.5 million (Q4 2025), and $272.6 million (Q3 2025), per Business Quant data.